{"id":"tivanisiran-sodium-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Conjunctival hyperemia"},{"rate":"5-10%","effect":"Eye pain"},{"rate":"5-10%","effect":"Foreign body sensation in the eye"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By targeting the SOD1 gene, tivanisiran sodium ophthalmic solution aims to reduce the production of superoxide dismutase 1 protein, which is implicated in the pathogenesis of glaucoma. This mechanism is based on the understanding that elevated levels of superoxide dismutase 1 protein contribute to the progression of glaucoma. By reducing the production of this protein, tivanisiran sodium ophthalmic solution may help slow or halt the progression of glaucoma.","oneSentence":"Tivanisiran sodium ophthalmic solution is an antisense oligonucleotide that targets the SOD1 gene to reduce the production of superoxide dismutase 1 protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:05.872Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of glaucoma"}]},"trialDetails":[{"nctId":"NCT04819269","phase":"PHASE3","title":"Tivanisiran for Dry Eye in Subjects With Sjögren's Syndrome","status":"COMPLETED","sponsor":"Sylentis, S.A.","startDate":"2021-05-25","conditions":"Dry Eye Disease, Sjögren Syndrome","enrollment":203},{"nctId":"NCT05310422","phase":"PHASE3","title":"Safety Study of Tivanisiran to Treat Dry Eye","status":"COMPLETED","sponsor":"Sylentis, S.A.","startDate":"2022-03-24","conditions":"Dry Eye Disease","enrollment":301}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Tivanisiran sodium ophthalmic solution","genericName":"Tivanisiran sodium ophthalmic solution","companyName":"Sylentis, S.A.","companyId":"sylentis-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tivanisiran sodium ophthalmic solution is an antisense oligonucleotide that targets the SOD1 gene to reduce the production of superoxide dismutase 1 protein. Used for Treatment of glaucoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}